SCHEMBL13628243

SCHEMBL13628243

CN1CCCC1CCNC(=O)c1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 1/20 0.37
POLB P06746 2/20 0.36
CACNA1G O43497 6/20 0.36
ACKR3 P25106 1/20 0.36
GALR3 O60755 1/20 0.36
NR2F2 P24468 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628233 0.87 CACNA1G (0.49) POLBCACNA1GALDH1A1
SCHEMBL13628237 0.87 POLB (0.39) TP53SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL13628241 0.87 CACNA1G (0.51) POLBCACNA1G
SCHEMBL13628176 0.85 POLB (0.40) SMN1; SMN2KMT2AMAPTPOLBGALR3
SCHEMBL13628187 0.85 POLB (0.51) SMN1; SMN2KMT2APOLBCACNA1GALDH1A1
SCHEMBL13628240 0.85 MAPT (0.46) TP53SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL13628228 0.83 POLB (0.38) SMN1; SMN2KMT2AMEN1MAPTPOLB
SCHEMBL13628232 0.83 POLB (0.39) TP53SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL13628238 0.82 POLB (0.36) TP53SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL13628235 0.82 ALDH1A1 (0.44) KMT2AMEN1POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 TP53 405/4885SMN1; SMN2 3544/4885KMT2A 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.